AU2015212265A1 - Anti-HER2 antibody-drug conjugate - Google Patents
Anti-HER2 antibody-drug conjugateInfo
- Publication number
- AU2015212265A1 AU2015212265A1 AU2015212265A AU2015212265A AU2015212265A1 AU 2015212265 A1 AU2015212265 A1 AU 2015212265A1 AU 2015212265 A AU2015212265 A AU 2015212265A AU 2015212265 A AU2015212265 A AU 2015212265A AU 2015212265 A1 AU2015212265 A1 AU 2015212265A1
- Authority
- AU
- Australia
- Prior art keywords
- drug conjugate
- her2 antibody
- her2
- antibody
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 108091008116 antibody drug conjugates Proteins 0.000 title 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020200596A AU2020200596B2 (en) | 2014-01-31 | 2020-01-29 | Anti-her2 antibody-drug conjugate |
| AU2022203818A AU2022203818A1 (en) | 2014-01-31 | 2022-06-02 | Anti-her2 antibody-drug conjugate |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014017777 | 2014-01-31 | ||
| JP2014-017777 | 2014-01-31 | ||
| JP2014-168944 | 2014-08-22 | ||
| JP2014168944 | 2014-08-22 | ||
| JP2014-227886 | 2014-11-10 | ||
| JP2014227886 | 2014-11-10 | ||
| PCT/JP2015/000355 WO2015115091A1 (en) | 2014-01-31 | 2015-01-28 | Anti-her2 antibody-drug conjugate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020200596A Division AU2020200596B2 (en) | 2014-01-31 | 2020-01-29 | Anti-her2 antibody-drug conjugate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015212265A1 true AU2015212265A1 (en) | 2016-05-12 |
| AU2015212265B2 AU2015212265B2 (en) | 2020-01-02 |
Family
ID=53756672
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015212265A Active 2036-10-08 AU2015212265B2 (en) | 2014-01-31 | 2015-01-28 | Anti-HER2 antibody-drug conjugate |
| AU2020200596A Active AU2020200596B2 (en) | 2014-01-31 | 2020-01-29 | Anti-her2 antibody-drug conjugate |
| AU2022203818A Pending AU2022203818A1 (en) | 2014-01-31 | 2022-06-02 | Anti-her2 antibody-drug conjugate |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020200596A Active AU2020200596B2 (en) | 2014-01-31 | 2020-01-29 | Anti-her2 antibody-drug conjugate |
| AU2022203818A Pending AU2022203818A1 (en) | 2014-01-31 | 2022-06-02 | Anti-her2 antibody-drug conjugate |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10155821B2 (en) |
| EP (4) | EP3101032B1 (en) |
| JP (8) | JP5998289B2 (en) |
| KR (12) | KR102275925B1 (en) |
| CN (2) | CN105829346B (en) |
| AU (3) | AU2015212265B2 (en) |
| BR (1) | BR112016013482B1 (en) |
| CA (1) | CA2928794C (en) |
| CY (2) | CY1121573T1 (en) |
| DK (2) | DK3466976T3 (en) |
| ES (2) | ES2727351T3 (en) |
| FR (1) | FR21C1030I2 (en) |
| HR (2) | HRP20211848T1 (en) |
| HU (3) | HUE044389T2 (en) |
| IL (4) | IL278891B1 (en) |
| LT (3) | LT3466976T (en) |
| MX (2) | MX2016006498A (en) |
| NL (1) | NL301117I2 (en) |
| NO (1) | NO2021027I1 (en) |
| NZ (1) | NZ719202A (en) |
| PH (1) | PH12016500904A1 (en) |
| PL (2) | PL3466976T3 (en) |
| PT (2) | PT3466976T (en) |
| RS (2) | RS62618B1 (en) |
| SG (2) | SG10201800210TA (en) |
| SI (2) | SI3101032T1 (en) |
| TW (9) | TWI796246B (en) |
| WO (1) | WO2015115091A1 (en) |
| ZA (1) | ZA201602802B (en) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3632471A1 (en) * | 2012-10-11 | 2020-04-08 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| KR102535900B1 (en) * | 2013-12-25 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | Anti-trop2 antibody-drug conjugate |
| SG10201800210TA (en) * | 2014-01-31 | 2018-02-27 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| ES2754348T3 (en) * | 2014-04-10 | 2020-04-17 | Daiichi Sankyo Co Ltd | Conjugate of (anti-HER2 antibody) -pharmaceutical |
| TWI695011B (en) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | Monoclonal antibodies against her2 epitope and methods of use thereof |
| US9808528B2 (en) | 2014-06-18 | 2017-11-07 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| EP4180455A1 (en) | 2015-06-29 | 2023-05-17 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| AU2017341000A1 (en) * | 2016-10-07 | 2019-04-11 | Daiichi Sankyo Company, Limited | Therapy for drug-resistant cancer by administration of anti-HER2 antibody/drug conjugate |
| AU2017377233A1 (en) | 2016-12-12 | 2019-06-13 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| CN117982673A (en) * | 2017-02-28 | 2024-05-07 | 第一三共株式会社 | Use of anti-HER 3 antibody-drug conjugates |
| CN108653746B (en) * | 2017-03-29 | 2021-04-27 | 北京键凯科技股份有限公司 | Multi-drug-loading-point high-drug-loading-rate ligand drug conjugate |
| BR112020003474A2 (en) | 2017-08-23 | 2020-10-20 | Daiichi Sankyo Company, Limited | pharmaceutical composition, and method for producing a pharmaceutical composition |
| CN117838880A (en) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | New method for preparing antibody-drug conjugate |
| SG11202000997YA (en) | 2017-08-31 | 2020-03-30 | Daiichi Sankyo Co Ltd | Improved method for producing antibody-drug conjugate |
| DK3794042T3 (en) | 2018-05-18 | 2024-04-15 | Daiichi Sankyo Co Ltd | ANTI-MUC1-EXATECET-ANTISTO-DRUG CONJUGATE |
| WO2019230645A1 (en) | 2018-05-28 | 2019-12-05 | 第一三共株式会社 | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate |
| CN112566942A (en) | 2018-07-25 | 2021-03-26 | 第一三共株式会社 | Efficient methods for making antibody-drug conjugates |
| JP7406488B2 (en) | 2018-07-27 | 2023-12-27 | 第一三共株式会社 | Protein that recognizes the drug site of the antibody-drug conjugate |
| EA202190403A1 (en) * | 2018-07-31 | 2021-05-24 | Дайити Санкио Компани, Лимитед | TREATMENT OF METASTATIC BRAIN TUMOR BY INJECTING AN ANTIBODY-DRUG CONJUGATE |
| CN110790840A (en) * | 2018-08-01 | 2020-02-14 | 三生国健药业（上海）股份有限公司 | Antibodies that bind to human HER2, methods of making and uses thereof |
| AU2019320336A1 (en) | 2018-08-06 | 2021-03-04 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and tubulin inhibitor |
| US20210340628A1 (en) | 2018-08-23 | 2021-11-04 | Daiichi Sankyo Company, Limited | Sensitivity marker for antibody-drug conjugate |
| BR112021004656A2 (en) | 2018-09-26 | 2021-06-01 | Jiangsu Hengrui Medicine Co., Ltd. | exatecan analogue drug-binding conjugate, method to prepare the same and application thereof |
| WO2020063673A1 (en) | 2018-09-30 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
| TW202034959A (en) | 2018-12-11 | 2020-10-01 | 日商第一三共股份有限公司 | Combination of antibody-drug conjugate and parp inhibitor |
| CN113195000A (en) * | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | Combination of antibody-drug conjugates and kinase inhibitors |
| CN109824759A (en) * | 2019-03-08 | 2019-05-31 | 联宁（苏州）生物制药有限公司 | A kind of Preparation Method And Their Intermediate of the drug-linker MC-MMAF for antibody drug conjugates |
| ES2930295T3 (en) | 2019-03-29 | 2022-12-09 | Medimmune Ltd | Compounds and conjugates thereof |
| CN111686259B (en) * | 2019-05-26 | 2023-08-08 | 成都百利多特生物药业有限责任公司 | SN 38-containing antibody drug conjugate |
| CN113766933A (en) * | 2019-06-28 | 2021-12-07 | 上海复旦张江生物医药股份有限公司 | Antibody coupling drug, intermediate thereof, preparation method and application |
| US20220411436A1 (en) * | 2019-09-18 | 2022-12-29 | Sichuan Baili Pharmaceutical Co., Ltd | Camptothecin derivative and conjugate thereof |
| MX2022005903A (en) | 2019-11-15 | 2022-12-13 | Seagen Inc | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate. |
| TW202128227A (en) | 2019-12-12 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Anti-claudin antibody-drug conjugate and pharmaceutical use thereof |
| KR20220113747A (en) | 2019-12-16 | 2022-08-16 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Conjugates of anti-CEA antibody-exatecan analogs and pharmaceutical uses thereof |
| EP4095148A4 (en) | 2020-01-22 | 2023-07-26 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof |
| AU2021240756A1 (en) | 2020-03-25 | 2022-11-17 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-PSMA antibody-exatecan analogue conjugate and medical use thereof |
| AU2021243073A1 (en) * | 2020-03-25 | 2022-10-13 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising antibody drug conjugate and use thereof |
| KR20220157425A (en) | 2020-03-25 | 2022-11-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Methods for preparing antibody drug conjugates |
| CN115835860A (en) * | 2020-06-12 | 2023-03-21 | 树顶分子生技股份有限公司 | Novel analogues of pterostilbene amino acids with carbonate for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
| WO2021260583A1 (en) * | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| TW202216207A (en) | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | Combination of antibody-drug conjugate and cdk9 inhibitor |
| WO2021260580A1 (en) * | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atm inhibitor |
| AU2021298251A1 (en) * | 2020-06-24 | 2023-02-02 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and ATR inhibitor |
| WO2021260582A1 (en) * | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
| WO2022001864A1 (en) * | 2020-06-28 | 2022-01-06 | 昆山新蕴达生物科技有限公司 | Antibody-drug conjugate and preparation method therefor and use thereof |
| CA3186675A1 (en) | 2020-07-20 | 2022-01-27 | Yasuki KAMAI | Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor |
| CA3188508A1 (en) * | 2020-08-13 | 2022-02-17 | Xiquan Zhang | Antibody drug conjugate |
| EP4211598A2 (en) | 2020-09-12 | 2023-07-19 | AstraZeneca UK Limited | A scoring method for an anti-her2 antibody-drug conjugate therapy |
| WO2022056696A1 (en) * | 2020-09-15 | 2022-03-24 | 四川百利药业有限责任公司 | Camptothecin drug and antibody conjugate thereof |
| CN116199739A (en) * | 2020-09-30 | 2023-06-02 | 映恩生物制药（苏州）有限公司 | Antitumor compound and preparation method and application thereof |
| US20230372527A1 (en) | 2020-10-09 | 2023-11-23 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| WO2022078259A1 (en) * | 2020-10-12 | 2022-04-21 | 四川百利药业有限责任公司 | Deuterated camptothecin derivative and antibody-drug conjugate thereof |
| CN114456186B (en) * | 2020-10-12 | 2023-10-20 | 成都百利多特生物药业有限责任公司 | Camptothecine derivative and ligand-drug conjugate thereof |
| US20230414778A1 (en) | 2020-11-11 | 2023-12-28 | Daiichi Sankyo Company, Limited | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY |
| WO2022102695A1 (en) | 2020-11-12 | 2022-05-19 | 第一三共株式会社 | Treatment for mesothelioma through administration of anti-b7-h3 antibody-drug conjugate |
| CN112535738B (en) * | 2020-12-04 | 2022-09-09 | 中国科学技术大学 | Oxaliplatin conjugate and preparation method and application thereof |
| JP2024503658A (en) * | 2021-01-13 | 2024-01-26 | メモリアル スローン－ケタリング キャンサー センター | Anti-DLL3 antibody-drug conjugate |
| WO2022171115A1 (en) * | 2021-02-09 | 2022-08-18 | 微境生物医药科技(上海)有限公司 | Camptothecin derivative for adc preparation |
| CN117015549A (en) * | 2021-03-17 | 2023-11-07 | 江苏恒瑞医药股份有限公司 | Preparation method of camptothecin derivative |
| CN116867789A (en) * | 2021-03-31 | 2023-10-10 | 上海复旦张江生物医药股份有限公司 | Preparation method of irinotecan derivative and intermediate thereof |
| WO2022236136A1 (en) * | 2021-05-07 | 2022-11-10 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
| CN113402584A (en) * | 2021-07-06 | 2021-09-17 | 联宁（苏州）生物制药有限公司 | Synthetic method of intermediate LND1067-L1 of antibody-coupled drug linker |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| TW202329936A (en) | 2021-11-18 | 2023-08-01 | 英商阿斯特捷利康英國股份有限公司 | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| WO2023126823A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
| WO2023126822A1 (en) * | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and rasg12c inhibitor |
| WO2023175483A1 (en) | 2022-03-16 | 2023-09-21 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
| TW202400140A (en) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
| TW202400650A (en) | 2022-05-11 | 2024-01-01 | 日商第一三共股份有限公司 | Combination of an antibody and cd47 inhibitor |
| WO2024015830A1 (en) | 2022-07-12 | 2024-01-18 | Cytomx Therapeutics, Inc. | Epcam immunoconjugates and uses thereof |
| WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
| CN117024438A (en) * | 2022-07-29 | 2023-11-10 | 杭州爱科瑞思生物医药有限公司 | Esatitecan derivative and application thereof |
| US20240116945A1 (en) * | 2022-09-02 | 2024-04-11 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3040121B2 (en) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | Methods of treating tumor cells by inhibiting growth factor receptor function |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5658920A (en) | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
| JP3008226B2 (en) | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | Hexacyclic compounds |
| JP4124480B2 (en) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
| DK0605522T3 (en) | 1991-09-23 | 2000-01-17 | Medical Res Council | Process for producing humanized antibodies |
| ES2227512T3 (en) | 1991-12-02 | 2005-04-01 | Medical Research Council | PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO. |
| JP3507073B2 (en) | 1992-03-24 | 2004-03-15 | ケンブリッジ アンティボディー テクノロジー リミティド | Methods for producing members of a specific binding pair |
| JP3359955B2 (en) | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | Antitumor agent |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
| US6504029B1 (en) | 1995-04-10 | 2003-01-07 | Daiichi Pharmaceutical Co., Ltd. | Condensed-hexacyclic compounds and a process therefor |
| JPH08337584A (en) | 1995-04-10 | 1996-12-24 | Dai Ichi Seiyaku Co Ltd | Condensed six-membered cyclic amino compound, medicine containing the same and production of the same |
| SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| JPH1095802A (en) | 1995-12-28 | 1998-04-14 | Tanabe Seiyaku Co Ltd | Camptothecine derivative |
| CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| JPH1171280A (en) | 1997-06-26 | 1999-03-16 | Tanabe Seiyaku Co Ltd | Medicine composition |
| JPH1192405A (en) | 1997-09-19 | 1999-04-06 | Dai Ichi Seiyaku Co Ltd | Medicinal complex |
| PT1071700E (en) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| AU3733399A (en) * | 1998-05-22 | 1999-12-13 | Daiichi Pharmaceutical Co., Ltd. | Drug composites |
| AU765409B2 (en) | 1998-10-30 | 2003-09-18 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
| PT1914244E (en) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Method of modulating the activity of functional immune molecules |
| HU230586B1 (en) | 1999-06-25 | 2017-02-28 | Genentech, Inc. | Use of an anti-erbb antibody-maytansinoid conjugates in the manufacture of a medicament for treating tumorous diseases |
| BR122014028365B8 (en) | 1999-06-25 | 2021-07-06 | Genentech Inc | manufactured article comprising a first container comprising a composition of humab4d5-8 contained therein and a second container comprising a composition of rhumab 2c4 contained therein |
| JP2002060351A (en) | 2000-03-22 | 2002-02-26 | Dai Ichi Seiyaku Co Ltd | Dds compound comprising drug having hydroxy group |
| AU2001267831A1 (en) | 2000-06-29 | 2002-01-08 | Daiichi Pharmaceutical Co., Ltd. | DDS compound and process for the preparation thereof |
| BR0112417A (en) | 2000-07-13 | 2003-07-01 | Daiichi Seiyaku Co | Pharmaceutical compositions containing dds compound |
| CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| TWI313609B (en) | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
| KR100573565B1 (en) | 2001-08-29 | 2006-04-25 | 주식회사 포스코 | Cylinder Ring with prominence and depression and mandrel with the same |
| BRPI0213846B8 (en) | 2001-11-01 | 2021-05-25 | Uab Research Foundation | composition comprising an antibody that specifically binds a trail receptor dr5 and one or more therapeutic agents |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| AU2003288467A1 (en) | 2002-12-13 | 2004-07-09 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| JP4942643B2 (en) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | Partially added antibodies and methods for conjugating them |
| CA2564076C (en) | 2004-05-19 | 2014-02-18 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| US7560111B2 (en) * | 2004-07-22 | 2009-07-14 | Genentech, Inc. | HER2 antibody composition |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| US7449184B2 (en) | 2005-01-21 | 2008-11-11 | Genentech, Inc. | Fixed dosing of HER antibodies |
| DE102005009099A1 (en) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | New camptothecin-peptide derivatives, useful for treating cancer |
| DE102005009084A1 (en) | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | New anthracyclin-peptide derivatives, useful for treating cancer, especially of the prostate, are cleaved, in the tumor, by prostate-specific antigen to release active antitumor agent and are transported by serum albumen |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| WO2007100385A2 (en) | 2005-10-31 | 2007-09-07 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
| US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| UA95958C2 (en) | 2006-05-30 | 2011-09-26 | Дженентек, Инк. | Antibody that binds to cd22, immunoconjugates and uses therefor |
| WO2007140371A2 (en) | 2006-05-30 | 2007-12-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| ITMI20061473A1 (en) | 2006-07-26 | 2008-01-27 | Indena Spa | DERIVATIVES OF CAMPTOTECIN WITH ANTITUMORAL ACTIVITY |
| EP3692988A3 (en) * | 2008-03-18 | 2020-10-14 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use |
| KR20230003298A (en) * | 2008-04-30 | 2023-01-05 | 이뮤노젠 아이엔씨 | Cross-linkers and their uses |
| US8541178B2 (en) | 2008-05-13 | 2013-09-24 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
| WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| PT3903829T (en) | 2009-02-13 | 2023-06-02 | Immunomedics Inc | Immunoconjugates with an intracellularly-cleavable linkage |
| JP5705836B2 (en) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Modulators for HER2 signaling in gastric cancer patients expressing HER2 |
| US20120171201A1 (en) | 2009-07-22 | 2012-07-05 | Enzon Pharmaceuticals, Inc. | Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| US20110042149A1 (en) | 2009-08-18 | 2011-02-24 | Baker Hughes Incorporated | Methods of forming polycrystalline diamond elements, polycrystalline diamond elements, and earth-boring tools carrying such polycrystalline diamond elements |
| EP2480230A4 (en) | 2009-09-24 | 2015-06-10 | Seattle Genetics Inc | Dr5 ligand drug conjugates |
| CA2782194C (en) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
| CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| SG185583A1 (en) | 2010-05-17 | 2012-12-28 | Livtech Inc | Anti-human trop-2 antibody having antitumor activity in vivo |
| AU2011255647A1 (en) | 2010-05-18 | 2012-11-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| EP2594589A1 (en) | 2010-06-10 | 2013-05-22 | Sapporo Medical University | ANTI-Trop-2 ANTIBODY |
| AR082205A1 (en) | 2010-07-12 | 2012-11-21 | Covx Technologies Ireland Ltd | CONJUGATES OF MULTIFUNCTIONAL ANTIBODIES |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| US20130330350A1 (en) | 2010-11-09 | 2013-12-12 | Medimmune, Llc | Antibody Scaffold For Homogenous Conjugation |
| JP5889912B2 (en) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | Alaninyl maytansinol antibody conjugate |
| AU2012335205A1 (en) | 2011-11-11 | 2014-05-29 | Rinat Neuroscience Corp. | Antibodies specific for Trop-2 and their uses |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| KR20140114826A (en) | 2011-12-14 | 2014-09-29 | 시애틀 지네틱스, 인크. | Fgfr antibody drug conjugates (adcs) and the use thereof |
| US20130280282A1 (en) | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
| CN104619350A (en) | 2012-06-14 | 2015-05-13 | Ambrx公司 | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
| EP3632471A1 (en) | 2012-10-11 | 2020-04-08 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| EP2927227A4 (en) * | 2013-01-03 | 2015-12-30 | Celltrion Inc | Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same |
| KR102535900B1 (en) | 2013-12-25 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | Anti-trop2 antibody-drug conjugate |
| SG10201800210TA (en) * | 2014-01-31 | 2018-02-27 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| KR102127623B1 (en) | 2014-04-10 | 2020-06-29 | 다이이찌 산쿄 가부시키가이샤 | Anti-her3 antibody-drug conjugate |
-
2015
- 2015-01-28 SG SG10201800210TA patent/SG10201800210TA/en unknown
- 2015-01-28 CN CN201580003121.4A patent/CN105829346B/en active Active
- 2015-01-28 PL PL18204861T patent/PL3466976T3/en unknown
- 2015-01-28 HU HUE15743738 patent/HUE044389T2/en unknown
- 2015-01-28 JP JP2015542503A patent/JP5998289B2/en active Active
- 2015-01-28 RS RS20211465A patent/RS62618B1/en unknown
- 2015-01-28 LT LTEP18204861.1T patent/LT3466976T/en unknown
- 2015-01-28 DK DK18204861.1T patent/DK3466976T3/en active
- 2015-01-28 EP EP15743738.5A patent/EP3101032B1/en active Active
- 2015-01-28 KR KR1020217009854A patent/KR102275925B1/en active IP Right Grant
- 2015-01-28 KR KR1020227022459A patent/KR102465042B1/en active IP Right Grant
- 2015-01-28 EP EP21187152.0A patent/EP3973995A1/en not_active Withdrawn
- 2015-01-28 ES ES15743738T patent/ES2727351T3/en active Active
- 2015-01-28 EP EP22198821.5A patent/EP4212552A1/en active Pending
- 2015-01-28 LT LTEP15743738.5T patent/LT3101032T/en unknown
- 2015-01-28 MX MX2016006498A patent/MX2016006498A/en active IP Right Grant
- 2015-01-28 CA CA2928794A patent/CA2928794C/en active Active
- 2015-01-28 EP EP18204861.1A patent/EP3466976B1/en active Active
- 2015-01-28 HU HUE18204861A patent/HUE057464T2/en unknown
- 2015-01-28 SI SI201530587T patent/SI3101032T1/en unknown
- 2015-01-28 KR KR1020217032820A patent/KR102362920B1/en active IP Right Grant
- 2015-01-28 PT PT18204861T patent/PT3466976T/en unknown
- 2015-01-28 PL PL15743738T patent/PL3101032T3/en unknown
- 2015-01-28 KR KR1020227038845A patent/KR102510128B1/en active IP Right Grant
- 2015-01-28 NZ NZ719202A patent/NZ719202A/en unknown
- 2015-01-28 IL IL278891A patent/IL278891B1/en unknown
- 2015-01-28 KR KR1020227004389A patent/KR102417312B1/en active IP Right Grant
- 2015-01-28 KR KR1020237040108A patent/KR20230162159A/en active Search and Examination
- 2015-01-28 DK DK15743738.5T patent/DK3101032T3/en active
- 2015-01-28 SG SG11201603960XA patent/SG11201603960XA/en unknown
- 2015-01-28 KR KR1020187031594A patent/KR102190548B1/en active IP Right Grant
- 2015-01-28 RS RS20190280A patent/RS58415B1/en unknown
- 2015-01-28 PT PT15743738T patent/PT3101032T/en unknown
- 2015-01-28 CN CN201910768778.XA patent/CN110464847B/en active Active
- 2015-01-28 BR BR112016013482-6A patent/BR112016013482B1/en active IP Right Grant
- 2015-01-28 IL IL310627A patent/IL310627A/en unknown
- 2015-01-28 KR KR1020217021044A patent/KR102314913B1/en active IP Right Grant
- 2015-01-28 KR KR1020167015961A patent/KR101916553B1/en active IP Right Grant
- 2015-01-28 HR HRP20211848TT patent/HRP20211848T1/en unknown
- 2015-01-28 SI SI201531748T patent/SI3466976T1/en unknown
- 2015-01-28 KR KR1020207035147A patent/KR102238848B1/en active IP Right Grant
- 2015-01-28 AU AU2015212265A patent/AU2015212265B2/en active Active
- 2015-01-28 ES ES18204861T patent/ES2895254T3/en active Active
- 2015-01-28 WO PCT/JP2015/000355 patent/WO2015115091A1/en active Application Filing
- 2015-01-28 KR KR1020237024073A patent/KR102606930B1/en active IP Right Grant
- 2015-01-28 KR KR1020237008409A patent/KR102557062B1/en active IP Right Grant
- 2015-01-30 TW TW111122225A patent/TWI796246B/en active
- 2015-01-30 TW TW112104986A patent/TW202322817A/en unknown
- 2015-01-30 TW TW111122223A patent/TWI796244B/en active
- 2015-01-30 TW TW111122224A patent/TWI796245B/en active
- 2015-01-30 TW TW110104664A patent/TWI789700B/en active
- 2015-01-30 TW TW108114649A patent/TWI722422B/en active
- 2015-01-30 TW TW107116039A patent/TWI661839B/en active
- 2015-01-30 TW TW111122222A patent/TWI796243B/en active
- 2015-01-30 TW TW104103127A patent/TWI627967B/en active
-
2016
- 2016-04-21 IL IL245252A patent/IL245252B/en active IP Right Grant
- 2016-04-22 ZA ZA2016/02802A patent/ZA201602802B/en unknown
- 2016-05-16 PH PH12016500904A patent/PH12016500904A1/en unknown
- 2016-05-18 MX MX2020010682A patent/MX2020010682A/en unknown
- 2016-07-28 US US15/221,851 patent/US10155821B2/en active Active
- 2016-08-29 JP JP2016166850A patent/JP6046301B1/en active Active
- 2016-11-16 JP JP2016222861A patent/JP6466895B2/en active Active
-
2017
- 2017-01-13 JP JP2017003826A patent/JP6105183B1/en active Active
-
2018
- 2018-09-13 US US16/130,615 patent/US11795236B2/en active Active
-
2019
- 2019-01-10 JP JP2019002311A patent/JP6665325B2/en active Active
- 2019-03-05 HR HRP20190431TT patent/HRP20190431T1/en unknown
- 2019-04-11 CY CY20191100406T patent/CY1121573T1/en unknown
- 2019-05-21 IL IL266790A patent/IL266790A/en active IP Right Grant
-
2020
- 2020-01-29 AU AU2020200596A patent/AU2020200596B2/en active Active
- 2020-02-19 JP JP2020025886A patent/JP6914380B2/en active Active
- 2020-08-19 US US16/997,613 patent/US11584800B2/en active Active
-
2021
- 2021-07-06 NO NO2021027C patent/NO2021027I1/en unknown
- 2021-07-06 HU HUS2100025C patent/HUS2100025I1/en unknown
- 2021-07-12 FR FR21C1030C patent/FR21C1030I2/en active Active
- 2021-07-13 LT LTPA2021515C patent/LTC3101032I2/lt unknown
- 2021-07-13 JP JP2021115436A patent/JP7146031B2/en active Active
- 2021-07-16 NL NL301117C patent/NL301117I2/en unknown
- 2021-11-30 CY CY20211101037T patent/CY1124774T1/en unknown
-
2022
- 2022-06-02 AU AU2022203818A patent/AU2022203818A1/en active Pending
- 2022-09-20 JP JP2022149242A patent/JP7467557B2/en active Active
-
2023
- 2023-09-12 US US18/367,446 patent/US20240026030A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2100025I1 (en) | Anti-her2 antibody-drug conjugate | |
| AU2015212265A1 (en) | Anti-HER2 antibody-drug conjugate | |
| EP3473270A4 (en) | Antibody-drug conjugate | |
| EP3137114B8 (en) | Anti-ptk7 antibody-drug conjugates | |
| EP3130608A4 (en) | (anti-her2 antibody)-drug conjugate | |
| ZA201700306B (en) | Her2 antibody-drug conjugates | |
| SG11201608309PA (en) | Anti-her3 antibody-drug conjugate | |
| EP3206710A4 (en) | Incretin-insulin conjugates | |
| EP3107557A4 (en) | Hydrophilic antibody-drug conjugates | |
| EP3119885A4 (en) | Antibody-fynomer conjugates | |
| EP3538098A4 (en) | Antibody-drug conjugates | |
| EP3152248A4 (en) | Dendrimer-drug conjugates | |
| AU2014902169A0 (en) | Dendrimer-drug conjugates |